Correction: Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

Mohammad Hashemi; Gholamreza Bahari; Jarosław Markowski; Andrzej Małecki; Marek J. Łos; Saeid Ghavami

doi:10.18632/oncotarget.27483

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis

PDF | How to cite

Oncotarget. 2020; 11:893-893. https://doi.org/10.18632/oncotarget.27483

Metrics: PDF 1278 views | ?

Mohammad Hashemi^1,2, Gholamreza Bahari², Jarosław Markowski³, Andrzej Małecki⁴, Marek J. Łos^5,8 and Saeid Ghavami^6,7

¹ Cellular and Molecular Research Center, Zahedan University of Medical Sciences, Zahedan, Iran
² Department of Clinical Biochemistry, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
³ ENT Department, School of Medicine, Medical University of Silesia in Katowice, Katowice, Poland
⁴ Faculty of Physiotherapy, The Jerzy Kukuczka Academy of Physical Education in Katowice, Katowice, Poland
⁵ Department of Molecular Biology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia in Katowice, Katowice, Poland
⁶ Department of Human Anatomy and Cell Science, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada
⁷ Health Policy Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
⁸ Centre de Biophysique Moléculaire, CNRS, Rue Charles Sadron, Orleans, France

Published: March 03, 2020

This article has been corrected: The Acknowledgements section has been updated. The proper text is as follows:

ACKNOWLEDGMENTS

SG was supported by CHRIM operating grant, Health Science Foundation general operating grant and Research Manitoba New Investigator operating grant. MJŁ kindly acknowledges the support from LE STUDIUM Institute for Advanced Studies (region Centre-Val de Loire, France) through its Smart Loire Valley General Program, cofunded by the Marie Sklodowska- Curie Actions, grant #665790.

Original article: Oncotarget. 2018; 9:24857–24868. DOI: https://doi.org/10.18632/oncotarget.25324.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27483

Publication Alerts

Post-Publication Promotion

Publication Discount

Corrections:

Correction: Association of PDCD6 polymorphisms with the risk of cancer: Evidence from a meta-analysis